French 
English 
Dutch Batch processing techniques
Explore pharmaceutical batch processing techniques, from stirred tank reactors and crystallization to filtration, centrifugation and extraction.
A defined toolkit of unit operations
The execution of a pharmaceutical batch process depends on a defined toolkit of unit operations, each selected and optimized for the chemical and physical transformations required at each stage of the synthesis or formulation workflow. The following sections describe the core techniques applied across reaction, crystallization, separation, and extraction operations in GMP batch manufacturing.
Batch processing techniques in pharmaceutical manufacturing
Pharmaceutical batch manufacturing relies on a combination of reaction, crystallization, separation and extraction techniques to produce active pharmaceutical ingredients (APIs) under controlled and reproducible conditions.
The execution of a pharmaceutical batch process depends on a defined toolkit of unit operations, each selected and optimized for the chemical and physical transformations required at each stage of the synthesis or formulation workflow.
The following sections describe the core techniques applied across reaction, crystallization, separation, and extraction operations in GMP batch manufacturing.
What are batch processing techniques in pharmaceutical manufacturing?
Batch processing is a manufacturing approach in which a defined quantity of materials is processed through a sequence of operations. Each stage is performed under established conditions, with process parameters monitored and documented to support product quality, reproducibility and traceability.
In pharmaceutical API manufacturing, a batch process may involve chemical synthesis, crystallization, solid-liquid separation, purification and drying. Depending on the chemistry and manufacturing requirements, these operations may be performed in separate equipment or combined within multifunctional systems.
The main techniques can be grouped into four categories:
Reaction techniques: chemical transformations performed under controlled mixing, temperature and atmospheric conditions.
Crystallization techniques: controlled formation of crystalline solids with the desired particle properties and solid form.
Separation techniques: isolation of solids from liquids through filtration, centrifugation or sedimentation.
Extraction techniques: selective transfer of compounds between liquid phases to recover or purify APIs and intermediates.
The selection and optimization of these techniques influence process yield, impurity removal, particle size distribution, solvent consumption and overall manufacturing efficiency.
Reaction techniques
Reaction techniques form the foundation of pharmaceutical batch synthesis. They provide the controlled environment required for chemical transformations, including reagent addition, mixing, heat transfer and protection of sensitive compounds.
Stirred tank batch reactors (STRs)
What is a stirred tank batch reactor?
A stirred tank reactor is the foundational vessel of pharmaceutical batch manufacturing. In its pharmaceutical form, the STR is typically a cylindrical, jacketed vessel fabricated from 316L stainless steel or glass-lined carbon steel.
It can be equipped with a:
- Variable-speed agitator
- Baffles
- Temperature sensors
- Pressure monitoring
- Inlet/outlet ports for reagent addition
- Sampling
- Product discharge
How are stirred tank reactors scaled for pharmaceutical manufacturing?
Vessel volumes in pharmaceutical API manufacturing range from laboratory scale (1,10 L) through pilot scale (50,500 L) to commercial scale (1,000,10,000 L). Geometric similarity between scales is maintained through defined scale-up parameters, principally impeller tip speed, power per unit volume (P/V), and mixing time.
The choice of impeller geometry, whether anchor, Rushton turbine, pitched blade, or retreat curve, is determined by the viscosity profile of the reaction mixture and the mass transfer requirements of the specific chemistry.
How is the reaction process monitored during batch manufacturing?
The STR provides a closed, controllable environment in which the following parameters are independently managed and recorded in the batch record: reaction temperature, agitation rate, reagent addition rate, and headspace atmosphere.
Inlet and outlet streams are equipped with flow meters or load cells that document reagent additions by mass or volume, creating a continuous process record from charge to discharge. Sampling ports allow in-process testing at defined intervals without breaking containment, supporting the IPT logic that governs progression through the batch manufacturing instruction.
How are highly exothermic reactions controlled?
For highly exothermic reactions, the jacketed STR provides the primary heat removal mechanism through circulation of a heat transfer fluid. The heat balance across the jacket is a critical process parameter.
During process development, reaction calorimetry establishes the heat of reaction and the maximum rate of heat evolution. This defines the safe operating envelope for addition rate and jacket temperature at each manufacturing scale.
The resulting data are captured in the process hazard analysis and referenced in the manufacturing instruction as safety-critical parameters.
Temperature-controlled synthesis
Temperature control in pharmaceutical batch reactors serves multiple simultaneous functions. It:
- Governs reaction rate through the Arrhenius relationship
- Determines selectivity between competing reaction pathways
- Controls the solubility of reagents and intermediates
- Defines the crystallization or precipitation behavior of the product
Precise, reproducible temperature management is therefore both a safety requirement and a quality-critical process parameter across the majority of pharmaceutical synthesis steps.
How is temperature controlled during batch synthesis?
Temperature-controlled synthesis in an STR is executed through a programmable jacket temperature control system, typically a circulating fluid unit (CFU) connected to the reactor jacket. The system is capable of both heating and cooling within a defined range, commonly -80 °C to + 200°C for pharmaceutical applications.
The control strategy specifies a temperature profile rather than a single setpoint, with defined ramps, holds, and transitions that match the reaction mechanism:
- A controlled exotherm management ramp during reagent addition
- An isothermal hold at the reaction temperature for the defined reaction time
- A controlled cooling profile ahead of crystallization or workup
How are cryogenic reactions managed?
For reactions requiring cryogenic conditions, typically -40 °C to -78 °C for enolization chemistry, asymmetric deprotonation, or reactions with thermally labile intermediates, dedicated low-temperature reactors with methanol/dry ice or liquid nitrogen cooling capacity are used.
At these temperatures, particularly in larger vessels where heat transfer through the batch becomes the limiting factor, temperature uniformity is addressed through agitation strategy and jacket temperature offset protocols developed during scale-up.
Temperature excursion monitoring is built into the batch record as a continuous data log rather than point measurements, with defined alert and action limits that trigger deviation procedures if the temperature profile deviates from the approved range.
This continuous logging, now standard through electronic batch record (EBR) systems, provides a complete thermal history of each batch that can be reviewed during quality release and referenced in any deviation investigation.
Inert atmosphere reactions (N₂, Ar)
A significant proportion of pharmaceutical synthesis steps require exclusion of atmospheric oxygen, moisture, or both, to prevent oxidative degradation of sensitive intermediates, protect catalysts from poisoning, or avoid side reactions with water. This is achieved through inert atmosphere techniques using nitrogen or argon as the blanketing gas, integrated into the STR design and the batch manufacturing procedure.
Nitrogen is the standard choice for inert atmosphere work in pharmaceutical manufacturing due to its low cost, ready availability in high-purity grades, and adequate performance for the majority of oxygen-sensitive reactions.
Argon is reserved for reactions where the higher density of argon provides better surface blanketing in open systems, or where the chemistry demands a noble gas environment, such as certain organolithium or Grignard reactions where even trace nitrogen reactivity is a concern.
How is an inert atmosphere established and maintained?
The inert atmosphere protocol for a batch reaction typically begins with a vessel inertisation sequence: evacuation of the vessel headspace followed by nitrogen backfill, repeated for three to five cycles to achieve a defined residual oxygen level, verified by inline oxygen analyser or documented as a procedural control.
Reagent additions under inert atmosphere are performed through nitrogen-purged addition funnels, dip tubes, or sealed transfer lines, with the vessel maintained under a positive nitrogen pressure throughout the addition sequence to prevent ingress.
For moisture-sensitive reactions, reagents and solvents are dried and transferred under nitrogen using established techniques: molecular sieve drying of solvents, Karl Fischer testing of reagent solutions ahead of use, and nitrogen-blanketed storage of sensitive materials as controlled materials within the batch manufacturing record.
The residual water content of critical reagents is specified as an in-process acceptance criterion and documented in the batch record as a prerequisite for the protected reaction step.
Crystallization techniques
Crystallization is a key operation in pharmaceutical API manufacturing, influencing product isolation, purity, particle size distribution and solid-state properties. Different crystallization techniques can be used to generate and control supersaturation, depending on API solubility, solvent selection and the desired crystalline product.
Cooling crystallization
Cooling crystallization exploits the temperature dependence of API solubility to drive supersaturation and crystal formation by reducing the temperature of a saturated or near-saturated solution in a controlled manner. It is the most widely used primary crystallization technique in pharmaceutical API manufacturing because it is operationally straightforward, mechanistically well-understood, and amenable to the precise temperature control available in jacketed STR systems.
The solubility curve of the API in the chosen solvent system is characterised during process development across the relevant temperature range, and the metastable zone width (MSZW), which defines the supersaturation region between the solubility limit and the spontaneous nucleation threshold, is established experimentally. The cooling profile is then designed to maintain supersaturation within the metastable zone throughout the crystallization, promoting controlled crystal growth on existing nuclei or seeds rather than uncontrolled bulk nucleation, which produces fine, poorly filterable crystals with high surface area and elevated impurity inclusion.
How does cooling rate influence crystal size and purity?
Cooling rate is the primary manipulated variable in cooling crystallization. Rapid cooling drives high supersaturation and generates a large number of small crystals with broad size distribution. Slow, programmed cooling maintains lower supersaturation levels and favors growth of fewer, larger crystals with narrower particle size distribution, better filterability, and lower impurity co-precipitation.
The optimal cooling profile is specific to each API and solvent system and is defined during process development through design of experiments (DoE) studies examining cooling rate, final temperature, and agitation rate as independent variables against crystal size distribution, yield, and purity as responses.
Anti-solvent addition
Anti-solvent crystallization is discussed in the context of API solid form development earlier in this article. As a technique, it merits additional consideration here from the perspective of process execution and control strategy in batch manufacturing.
The controlled addition of anti-solvent to an API solution generates supersaturation through dilution of the solvating phase rather than temperature change, making it applicable to compounds with flat or inverted solubility-temperature profiles.
The rate and profile of anti-solvent addition governs the supersaturation trajectory in the same way that cooling rate governs cooling crystallization, and the same metastable zone logic applies: addition at a rate that maintains supersaturation within the MSZW promotes controlled nucleation and growth rather than oiling-out or amorphous precipitation.
How is anti-solvent addition controlled during batch crystallization?
In batch practice, anti-solvent is added via a metered pump or mass flow controller at a defined rate (expressed as volumes of anti-solvent per volume of product solution per unit time), with the addition rate profiled, typically starting slowly to initiate controlled nucleation, then increasing once a stable crystal suspension is established.
The batch record documents the addition rate profile, total anti-solvent volume, addition temperature, and agitation rate as critical process parameters, with in-process suspension density or turbidity monitoring used to track crystallization progress.
Solvent, residual anti-solvent composition in the mother liquor at the end of crystallization determines the residual solvent content in the isolated solid, and the anti-solvent volume and wash protocol are optimized to achieve compliance with ICH Q3C residual solvent specifications.
Seeded crystallization
Seeded crystallization is the controlled introduction of small quantities of pre-characterized API crystals into a supersaturated solution to direct nucleation onto the desired solid form, suppress spontaneous nucleation of unwanted polymorphs or habits, and improve crystal size distribution reproducibility.
It is standard practice in commercial pharmaceutical API crystallization and is considered a quality-critical process step in polymorphically complex systems.
Seeds are produced and characterized as a controlled material within the manufacturing system: they are manufactured to a defined particle size (typically 10,50 µm, achieved by milling), verified for polymorphic form by XRPD and DSC, and stored under conditions that maintain their crystalline integrity, typically in sealed containers under nitrogen at controlled temperature.
Seed lot identity, particle size, polymorphic form, and purity are documented and linked to the batch record of each crystallization in which they are used.
Which parameters determine successful seeded crystallization?
The seeding protocol specifies the supersaturation at which seeds are added (the seed point), which is defined relative to the solubility curve and MSZW, seed loading (typically 0.1,1.0% w/w of the theoretical API yield), method of addition (slurried in a small volume of the crystallization solvent to ensure even distribution), and the post-seed agitation period before the cooling or anti-solvent addition profile continues.
The seed point is critical: addition at too low a supersaturation results in seed dissolution rather than crystal growth, while addition at too high a supersaturation results in spontaneous nucleation that overwhelms the seeded growth mechanism and produces a bimodal crystal size distribution.
Controlled nucleation and growth
Beyond seeding, pharmaceutical crystallization process design increasingly incorporates explicit strategies for controlling the nucleation and growth phases as independent events, recognizing that the properties of the final crystalline product are determined by the balance between nucleation rate (which determines the number of crystals) and growth rate (which determines their size).
In a controlled nucleation and growth strategy, nucleation is induced at a defined, controlled supersaturation, either through seeding, through a brief temperature undershoot below the nucleation threshold followed by return to the metastable zone, or through localized addition of a small volume of anti-solvent to generate a nucleation burst.
Once a defined crystal count is established (monitored by FBRM as a real-time particle count measurement), the supersaturation is reduced to a level that supports growth but suppresses further nucleation, and the crystallization is then driven by slow depletion of dissolved API through programmed cooling or anti-solvent addition.
How is crystallization monitored using a PAT
PAT tools are central to controlled nucleation and growth strategies in modern pharmaceutical batch crystallization. FBRM provides real-time chord length distribution data that tracks crystal count and size evolution throughout the crystallization.
Inline UV/Vis or NIR concentration probes monitor dissolved API concentration, allowing the supersaturation to be calculated in real time relative to the solubility curve. Inline Raman or NIR spectroscopy confirms polymorphic form during crystallization, providing an early warning of unwanted form transitions before the batch is isolated.
These data streams are integrated into the batch record as continuous process logs and support real-time release testing (RTRt) strategies where regulatory frameworks permit.
Comparison of pharmaceutical crystallization techniques
| Technique | Main purpose | Main control parameter |
|---|---|---|
| Cooling crystallization | Form crystals | Cooling rate |
| Anti-solvent crystallization | Reduce solubility | Anti-solvent addition rate |
| Seeded crystallization | Control nucleation | Seed loading |
| Controlled nucleation | Improve particle size | Supersaturation |
The selection of a crystallization technique depends on the properties of the API, the solvent system and the desired characteristics of the isolated solid.
Separation techniques
Solid-liquid separation is an essential operation in pharmaceutical batch manufacturing, particularly during API isolation, catalyst recovery and reaction workup. Filtration, centrifugation and decantation are used to separate solids from liquid phases, with the selection depending on particle properties, process requirements and containment considerations.
Filtration (vacuum and pressure)
Filtration is the primary solid-liquid separation technique in pharmaceutical batch manufacturing, applied at multiple stages, including isolation of crystallised API, recovery of spent catalyst, removal of inorganic salts from reaction workup, and clarification of solutions ahead of crystallization.
The choice between vacuum and pressure filtration depends on the particle size and filterability of the solid, the throughput requirement, and the containment requirements of the product.
Vacuum filtration and agitated Nutsche filter-dryers
Vacuum filtration using a Büchner or pressure Nutsche filter (agitated Nutsche filter-dryer, ANFDs, being the standard for GMP pharmaceutical operations) draws the mother liquor through the filter cake by applying vacuum below the filter medium. The ANFD is the workhorse of pharmaceutical API isolation: it combines filtration, washing, and vacuum drying in a single contained vessel, which eliminates the product transfer steps that would otherwise represent containment, contamination, and yield loss risks in open systems.
The agitator allows the filter cake to be reslurried with wash solvent, improving impurity and solvent removal compared to displacement washing alone.
Pressure filtration
Pressure filtration applies positive pressure above the filter cake to drive the liquid phase through the filter medium, offering higher driving force than vacuum filtration for slow-filtering materials. It is used for fine-particle suspensions where vacuum filtration would result in unacceptably slow filtration rates or where the compressibility of the cake under vacuum creates a low-permeability layer that limits throughput.
Pressure leaf filters and pressure plate filters are used in pharmaceutical manufacturing for catalyst recovery and process stream clarification.
Filter medium selection, sintered metal, filter paper, polypropylene cloth, or membrane, is based on the particle size of the solid, compatibility with the solvent system, and the requirement for extractable and leachable control in GMP applications. Filter medium specifications and change frequency are controlled as part of the batch manufacturing procedure.
Centrifugation
Centrifugation achieves solid-liquid separation by applying centrifugal force to a suspension, driving the denser solid phase to the wall of the centrifuge basket while the liquid phase passes through the filter medium. In pharmaceutical API manufacturing, the basket centrifuge (perforated bowl with filter cloth) is the most widely used configuration, operated in batch mode with a charge, spin, wash, and discharge cycle that maps directly onto the batch production logic.
How does centrifugation affect API isolation?
The centrifugal force applied (expressed as multiples of gravitational acceleration, g) and the spin time determine the residual mother liquor content of the centrifuge cake, which directly affects the residual impurity and solvent content of the isolated solid.
Process development establishes the minimum spin time and g-force required to achieve a cake moisture content consistent with downstream drying targets and residual solvent specifications.
When is centrifugation preferred over filtration?
Centrifugation is preferred over filtration for certain particle morphologies, particularly plate-like or needle crystals that form highly compressible, low-permeability filter cakes under vacuum or pressure.
It is also the separation method of choice where the product is susceptible to mechanical degradation by the agitator in an ANFD or where the particle size distribution of the isolated solid must be preserved without attrition.
What are the containment requirements for pharmaceutical centrifugation?
Containment is a significant consideration in pharmaceutical centrifugation for potent compounds. Contained centrifuge designs with nitrogen purging and glove box discharge capability are standard for highly active APIs, with containment performance validated to defined operator exposure limits (OELs) as part of the facility qualification program.
Decantation
Decantation, the separation of a liquid phase from a settled or sedimented solid by gravity, is used in pharmaceutical batch manufacturing as a supplementary or preliminary separation technique rather than a primary isolation method.
It is applied principally to remove the bulk of the mother liquor from a crystalline suspension before transfer to a filtration or centrifugation step, reducing the volume and time requirements of the subsequent separation.
How is decantation performed in a batch reactor?
In a batch STR, decantation is performed by allowing the solid to settle under gravity or with gentle agitation reduction, then removing the supernatant through a dip tube or outlet positioned above the settled bed. The supernatant is assayed for dissolved product content to confirm that yield loss through decantation is within acceptable limits before transfer.
For fast-settling, dense crystal morphologies, decantation can remove 60,80% of the mother liquor volume in a short hold time, substantially reducing the wash solvent volumes required in the subsequent filtration step and improving the efficiency of the overall isolation sequence.
Comparison of solid-liquid separation techniques
| Technique | Separation principle | Main application |
|---|---|---|
| Filtration | Pressure differential through a filter medium | API isolation, catalyst recovery and clarification |
| Centrifugation | Centrifugal force | Solid-liquid separation and cake dewatering |
| Decantation | Gravity settling | Preliminary removal of mother liquor |
The appropriate technique depends on the properties of the suspension and the requirements of the subsequent manufacturing steps.
Extraction techniques
Extraction techniques are used in pharmaceutical batch processing to recover or purify compounds based on their distribution between different liquid phases.
Liquid-liquid extraction and acid-base extraction are particularly relevant during reaction workup and the purification of pharmaceutical intermediates and APIs.
Liquid-liquid extraction
Liquid-liquid extraction as a purification strategy in pharmaceutical batch workup is discussed in detail in the workup and purification section of this article. As an applied technique in batch manufacturing, its execution depends on vessel geometry, phase volume ratios, and mixing strategy optimized for efficient mass transfer between phases without emulsion formation.
How is liquid-liquid extraction performed in a batch vessel?
In a batch vessel, LLE is performed by adding the extractant solvent to the product solution, mixing for a defined period at a controlled agitation rate, and then allowing the phases to separate under gravity before draining the lower phase through the vessel outlet and recovering the upper phase via dip tube or overflow.
The mixing intensity is a critical parameter: vigorous mixing improves mass transfer and extraction efficiency but increases the risk of emulsion formation for surface-active impurities or at certain solvent-water ratios. Process development establishes the minimum mixing time and agitation rate that achieves equilibrium partitioning without emulsification, expressed as a defined impeller speed and mixing duration in the manufacturing instruction.
How does phase volume ratio influence extraction efficiency?
Phase volume ratio is optimized to maximize the ratio of solute concentration in the extract phase to the raffinate phase, governed by the distribution coefficient D at the operating pH and temperature. For multi-stage extraction, the total extractant volume is typically more efficiently deployed as two or three smaller-volume extractions than a single large-volume extraction, as the staged contact improves overall recovery for compounds with moderate distribution coefficients.
The batch process accommodates multi-stage LLE as sequential operations within the same vessel, with each extraction cycle documented in the batch record as a discrete step with defined volumes, mixing parameters, and phase separation confirmation.
Acid-base extraction
Acid-base extraction is a selective variant of LLE that exploits the pH-dependent ionisation of basic or acidic APIs and impurities to direct partitioning between organic and aqueous phases.
Because ionised species are effectively insoluble in non-polar organic solvents, adjusting the pH of the aqueous phase controls whether a compound partitions into the organic layer (unionised form, favoured by pH remote from pKa) or the aqueous layer (ionized form, favoured by pH within 2 units of pKa).
This selectivity makes acid-base extraction one of the most powerful and widely used purification tools in small-molecule pharmaceutical synthesis.
How does acid-base extraction work for basic APIs?
The standard acid-base extraction workflow for a basic API proceeds in two stages. In the first, the crude product mixture in organic solvent is washed with acidic aqueous solution (typically dilute HCl or H₂SO₄ at pH 1,3), which protonates the basic API and transfers it into the aqueous phase as its salt, separating it from non-basic neutral and acidic impurities that remain in the organic layer.
In the second stage, the acidic aqueous extract is treated with base (aqueous NaOH, K₂CO₃, or NH₃ solution) to raise the pH above the pKa of the API by at least 2 units, deprotonating the API and driving it back into a fresh organic solvent layer. This back-extraction recovers the API in a purified organic solution, substantially free of the neutral and basic impurities that partitioned differently across the two stages.
Which parameters determine acid-base extraction selectivity?
The selectivity of acid-base extraction is determined by the difference in pKa values between the API and the impurities to be removed. Process development maps the partitioning behaviour of the API and each key impurity as a function of pH, establishing the operating pH windows for the acidic wash and the basic back-extraction that maximise API recovery while achieving the required impurity rejection.
These pH windows are specified as critical process parameters in the manufacturing instruction, with defined acceptance limits and measurement requirements documented in the batch record at each extraction step.
How is acid-base extraction applied to acidic and amphoteric compounds?
For acidic APIs, the logic is reversed: basic aqueous wash transfers the deprotonated API into the aqueous phase, and acidification of the extract drives back-extraction into organic solvent. For amphoteric compounds with both acidic and basic functionality, the extraction strategy is designed around the net charge at each operating pH, requiring careful pKa characterization of all ionizable groups.
Acid-base extraction also serves as a primary purification tool for removal of basic amine impurities from neutral product streams, acidic catalyst residues, and buffer components from enzymatic synthesis steps.
In each case, the principle is the same: pH-directed differential partitioning converts a chemically similar mixture into a separable distribution across two phases, with the batch vessel providing the controlled environment in which the pH adjustments, mixing, and phase separations are executed and documented in sequence.
Discuss your application with our Xperts
Our Xperts are happy to discuss your application and help you find the right solution.
FAQ
What is temperature-controlled synthesis?
Temperature-controlled synthesis uses programmed heating and cooling profiles throughout a reaction. These profiles may include controlled ramps, holding periods, and cooling phases to optimize reaction performance and product quality.
Why are cryogenic reactions used in pharmaceutical manufacturing?
Cryogenic conditions are often required for highly reactive intermediates, asymmetric synthesis, organometallic chemistry, and reactions that require tight control of side reactions.
What is an inert atmosphere reaction?
An inert atmosphere reaction is performed under nitrogen or argon to prevent oxygen or moisture from reacting with sensitive reagents, intermediates, or catalysts.
What is cooling crystallization?
Cooling crystallization is a process in which a solution is cooled under controlled conditions to reduce solubility and promote crystal formation.
What is seeded crystallization?
Seeded crystallization involves adding pre-characterized crystals to a supersaturated solution to direct crystal growth and reduce unwanted nucleation.
What is polymorph control in pharmaceutical crystallization?
Polymorph control ensures that the desired crystal form is consistently produced. Different polymorphs can exhibit different stability, solubility, dissolution rates, and bioavailability.
What is controlled nucleation and crystal growth?
Controlled nucleation and growth separates crystal formation into two stages: first establishing a controlled number of crystal nuclei, then promoting crystal growth while minimizing further nucleation.
What is the difference between vacuum filtration and pressure filtration?
Vacuum filtration uses reduced pressure beneath the filter medium to pull liquid through the filter cake, while pressure filtration uses positive pressure above the material to push liquid through the filter.
What is acid-base extraction?
Acid-base extraction is a purification technique that uses pH changes to selectively move ionizable compounds between organic and aqueous phases.